Trial Profile
MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms MALIBU
- 09 May 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2020 Planned number of patients changed from 160 to 175.
- 08 Oct 2019 Status changed from not yet recruiting to recruiting.